ARTICLE | Clinical News
FDA approves Symbicort to reduce COPD exacerbations
October 20, 2017 12:32 AM UTC
In September, FDA approved Symbicort budesonide/formoterol from AstraZeneca plc (LSE:AZN; NYSE:AZN) to reduce exacerbations of chronic obstructive pulmonary disorder (COPD). The combination of budeson...
BCIQ Company Profiles